2024年7月5日 · This real-world retrospective cohort study using Australian Pharmaceutical Benefits Scheme (PBS) 10% investigated changes in chronic lymphocytic leukemia (CLL) treatment by line of therapy, time-to-next-treatment, treatment duration, and overall survival (OS).

2023年3月7日 · Chronic lymphocytic leukemia is a chronic lymphoproliferative disorder characterized by monoclonal B cell proliferation. It is the most common adult leukemia in Western populations and comprises 25 to 30 percent of leukemias in the United States.

2018年6月21日 · CLL or SLL might be suspected in otherwise healthy adults who have an absolute increase in clonal B lymphocytes, but who have <5 × 10 9 /L B lymphocytes in the blood.

2023年12月7日 · Chronic lymphocytic leukemia (chronic lymphoid leukemia, CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally incompetent lymphocytes...

2023年9月24日 · The WHO 2017 9 and NCCN 2020 10 guidelines for the diagnosis of CLL require ≥5 × 10 9 /L circulating monoclonal B-lymphocytes with a typical CLL immunophenotype in the PB. 12 The diagnosis of small lymphocytic lymphoma (SLL) is made if the circulating clone is <5 × 10 9 /L with nodal, splenic or other extramedullary involvement and is ...

2020年11月18日 · Acalabrutinib (Calquence®) has been available on the Pharmaceutical Benefits Scheme (PBS) for CLL and SLL since September 1 for the treatment of patients with relapsed or refractory CLL/SLL who are not suitable for treatment or retreatment with a purine analogue (also known as second line treatment of CLL/SLL).

Real world study investigating treatment and outcomes of CLL patients in Australia.

Patients must be eligible for the PBS and meet the relevant restriction criteria. The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing idelalisib. …

The Federal Minister for Health, The Hon. Greg Hunt MP, has announced that CLL patients unsuitable for standard chemotherapy -based treatments will now have access through the PBS to venetoclax in combination with obinutuzumab as a first line combination treatment option.

2012年11月16日 · The NF-κB signaling pathway is constitutively activated in chronic lymphocytic leukemia (CLL). Aberrant activation of the p65 (RelA) subunit of NF-κB is associated with chemoresistance, a shorter lymphocyte doubling time and poor overall survival (OS) in CLL.